Photodynamic diagnosis in patients with T1G3 bladder cancer: Influence on recurrence rate

World Journal of Urology

Volumn 28, Issue 4, 2010, Pages 407-411

  Stanislaus, Peter ^a,c   Zaak, Dirk ^a,c   Stadler, Thomas ^a   Tritschler, Stefan ^a   Knüchel, Ruth ^b   Stief, Christian G ^a   Karl, Alexander ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c Department of Urology ^*  (Germany)

Author keywords

Fluorescence endoscopy; Influence; PDD; Recurrence rate; T1G3 bladder cancer

Indexed keywords

5-AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PHOTOSENSITIZING AGENT;

AGED; ARTICLE; BLADDER TUMOR; CARCINOMA IN SITU; CYSTOSCOPY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MALE; METHODOLOGY; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICS; TUMOR RECURRENCE; ANALOGS AND DERIVATIVES; DIAGNOSTIC USE; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; STATISTICS AND NUMERICAL DATA; URINARY BLADDER NEOPLASMS;

AGED; AMINOLEVULINIC ACID; CARCINOMA IN SITU; CYSTOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOTOSENSITIZING AGENTS; PROGNOSIS; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; KAPLAN-MEIER ESTIMATE;

EID: 77954862796     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0574-y     Document Type: Article

References (21)

1. Soloway MS, Sofer M, Vaidya A (2002) Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167: 1573-1583.
2. Denzinger S, Burger M, Walter B, Knuechel R, Roessler W, Wieland WF, Filbeck T (2007) Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8 year results of prospective randomized study. Urology 69: 675-679.
3. Herr HW (1997) Tumour progression, survival in patients with T1G3 bladder tumours, 15 year outcome. Br J Urol 80: 762-765.
4. Bono AV, Lovisolo JA, Saredi G (2003) Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer. Eur Urol 37: 478-483.
5. Catanzaro F, Torelli F, Catanzaro M, Cappellano F, Pizzoccaro M, Baruffi M, Sironi D, Pozzoli GL (1996) Conservative treatment of high-risk (T1G3) transitional carcinoma. Arch Ital Urol Androl 68: 21-24.
6. Cheng L, Weaver AL, Neumann RM, Scherer BG, Bostwick DG (1999) Sub staging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer 86: 1035-1043.
7. Patard J, Moudouni S, Saint F, Rioux-Leclercq N, Manunta A, Guy L, Ballanger P, Lanson Y, Hajri M, Irani J, Guille F, Beurton D, Lobel B (2001) Tumour progression and survival in patients with T1G3 bladder tumours: multicentric retrospective study comparing 94 patients treated during 17 years. Urology 58: 551-556.
8. van der Meijden AP, Sylvester R, Oosterlinck W, Solsona E, Boehle A, Lobel B, Rintala E (2005) EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 48: 363-371.
9. Hungerhuber E, Stepp H, Kriegmair M, Stief C, Hofstetter A, Hartmann A, Knuechel R, Karl A, Tritschler S, Zaak D (2007) Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 69: 260-264.
10. Kriegmair M, Zaak D, Stepp H, Stepp H, Baumgartner R, Knuechel R, Hofstetter A (1999) Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. Eur Urol 36: 386-392.
11. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 163: 1124-1129.
12. Bohle A, Bock PR (2004) Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology 63: 682-686.
13. Herr HW, Dalbagni G (2003) Defining bacillus Calmette-Guerin refractory superficial bladder tumours. J Urol 169: 1706-1708.
14. Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, Donat MS, Herr HW, Sogani P, de Palma D, Bajorin D (2002) Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin 20: 3193-3198.
15. Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S (2000) The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164: 685-689.
16. Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W (2002) Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumour. J Urol 168: 67-71.
17. Schumacher MC, Holmang S, Davidsson T, Friedrich B, Pedersen J, Wiklund NP (2010) Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol 57: 293-299.
18. Jakse G, Algaba F, Malmstrom PU, Oosterlinck W (2004) A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 45: 539-546.
19. Kriegmair M, Zaak D, Rothenberger KH, Rassweiler J, Jocham D, Eisenberger F, Tauber R, Stenzl A, Hofstetter A (2002) Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 168: 475-478.
20. Sylvester RJ (2007) Intravesical chemotherapy in non-muscle-invasive bladder cancer: what schedule and duration of treatment? Eur Urol 52: 951-953.
21. Jocham D, Witjes F, Wagner S, Zeylemaker B, van MJ, Grimm MO, Muschter R, Popken G, Konig F, Knuchel R, Kurth KH (2005) Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 174: 862-866.